KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Accumulated Expenses (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Accumulated Expenses for 17 consecutive years, with $172.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 38.73% to $172.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $172.3 million, a 38.73% increase, with the full-year FY2025 number at $172.3 million, up 38.73% from a year prior.
  • Accumulated Expenses was $172.3 million for Q4 2025 at Bio-Rad Laboratories, down from $182.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $277.0 million in Q4 2021 to a low of $124.2 million in Q4 2024.
  • A 5-year average of $176.1 million and a median of $173.9 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: decreased 29.68% in 2022, then soared 38.73% in 2025.
  • Bio-Rad Laboratories' Accumulated Expenses stood at $277.0 million in 2021, then decreased by 29.68% to $194.8 million in 2022, then fell by 28.18% to $139.9 million in 2023, then decreased by 11.22% to $124.2 million in 2024, then surged by 38.73% to $172.3 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Accumulated Expenses are $172.3 million (Q4 2025), $182.8 million (Q3 2025), and $157.8 million (Q2 2025).